福元醫藥(601089.SH):酮洛芬貼劑獲得藥物臨牀試驗批準通知書
格隆匯6月5日丨福元醫藥(601089.SH)公佈,公司收到了國家藥品監督管理局覈準簽發的酮洛芬貼劑的《藥物臨牀試驗批準通知書》。公司申請藥物臨牀試驗的酮洛芬貼劑,適應症爲適用於鎮痛消炎(腰痛、骨關節炎、肩周炎、肌腱及腱鞘炎、肌腱周圍炎、肱骨外上髁炎、肌肉痛、創傷後腫脹疼痛等)、類風溼性關節炎的關節局部鎮痛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.